WO2003002518A1 - Nouveaux derives de 2,4-difluorobenzamide utilises comme agents antiviraux - Google Patents
Nouveaux derives de 2,4-difluorobenzamide utilises comme agents antiviraux Download PDFInfo
- Publication number
- WO2003002518A1 WO2003002518A1 PCT/KR2002/001239 KR0201239W WO03002518A1 WO 2003002518 A1 WO2003002518 A1 WO 2003002518A1 KR 0201239 W KR0201239 W KR 0201239W WO 03002518 A1 WO03002518 A1 WO 03002518A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indazolyl
- difluoro
- group
- benzamide
- branched
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010037547A KR100713137B1 (ko) | 2001-06-28 | 2001-06-28 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
KR2001/37547 | 2001-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003002518A1 true WO2003002518A1 (fr) | 2003-01-09 |
Family
ID=19711456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2002/001239 WO2003002518A1 (fr) | 2001-06-28 | 2002-06-28 | Nouveaux derives de 2,4-difluorobenzamide utilises comme agents antiviraux |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100713137B1 (fr) |
WO (1) | WO2003002518A1 (fr) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005000308A2 (fr) * | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Procedes d'identification des inhibiteurs de la polymerase vhc-ns5b et utilisations associees |
WO2005080388A1 (fr) | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Inhibiteurs de la polymerase virale |
JP2006517574A (ja) * | 2003-02-14 | 2006-07-27 | グラクソ グループ リミテッド | カルボキサミド誘導体 |
WO2007061670A1 (fr) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Modulateurs de beta-secretase et procedes d'utilisation associes |
WO2007062007A1 (fr) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Modulateurs de la bêta-secrétase et procédés d'utilisation de ceux-ci |
WO2007061930A1 (fr) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Modulateurs de beta-secretase et procedes d'utilisation |
WO2008005511A2 (fr) * | 2006-07-05 | 2008-01-10 | Intermune, Inc. | Nouveaux inhibiteurs de la réplication du virus de l'hépatite c |
WO2008147544A1 (fr) | 2007-05-25 | 2008-12-04 | Amgen Inc. | Composés d'hydroxyéthylamine substitués en tant que modulateurs de la bêta-sécrétase et méthodes d'utilisation |
US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
WO2011063233A1 (fr) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Composés amino hétéroaryles comme modulateurs de la bêta-secrétase et procédés d'utilisation |
WO2011063272A1 (fr) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Composés amino hétéroaryliques comme modulateurs de bêta-sécrétase et procédés d'utilisation |
WO2011090911A1 (fr) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Composés d'aminohétéroaryle en tant que modulateurs de bêta-sécrétase et procédés d'utilisation |
US8163909B2 (en) | 2007-05-25 | 2012-04-24 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
EP2494991A1 (fr) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Polythérapie pour le traitement de l'infection par VHC |
US8426447B2 (en) | 2008-09-11 | 2013-04-23 | Amgen Inc. | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use |
US8497264B2 (en) | 2010-03-15 | 2013-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US8633228B2 (en) | 2008-08-01 | 2014-01-21 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and pest controlling method |
WO2014033167A1 (fr) * | 2012-08-28 | 2014-03-06 | Janssen R&D Ireland | Dérivés de sulfamoyle bicycliques fusionnés et leur utilisation en tant que médicaments pour le traitement de l'hépatite b |
US8883782B2 (en) | 2010-03-15 | 2014-11-11 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
US9296759B2 (en) | 2011-09-21 | 2016-03-29 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9862707B2 (en) * | 2014-03-26 | 2018-01-09 | Merck Sharp & Dohme Corp. | TrkA kinase inhibitors, compositions and methods thereof |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10196376B2 (en) | 2011-12-21 | 2019-02-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10398677B2 (en) | 2013-04-03 | 2019-09-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10457638B2 (en) | 2013-05-17 | 2019-10-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10632112B2 (en) | 2014-02-05 | 2020-04-28 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US10676429B2 (en) | 2012-08-28 | 2020-06-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11129834B2 (en) | 2016-04-15 | 2021-09-28 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3857853A (en) * | 1973-04-23 | 1974-12-31 | Lilly Co Eli | 3-alkyl-5-(alpha-cyanobenzylidene) oxazolidine-2,4-diones |
US4486601A (en) * | 1983-08-19 | 1984-12-04 | Pennwalt Corporation | Esters of 2-adamantanone oxime |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5839127B2 (ja) * | 1978-03-09 | 1983-08-27 | 明治製菓株式会社 | 除草剤組成物 |
-
2001
- 2001-06-28 KR KR1020010037547A patent/KR100713137B1/ko not_active IP Right Cessation
-
2002
- 2002-06-28 WO PCT/KR2002/001239 patent/WO2003002518A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3857853A (en) * | 1973-04-23 | 1974-12-31 | Lilly Co Eli | 3-alkyl-5-(alpha-cyanobenzylidene) oxazolidine-2,4-diones |
US4486601A (en) * | 1983-08-19 | 1984-12-04 | Pennwalt Corporation | Esters of 2-adamantanone oxime |
Non-Patent Citations (2)
Title |
---|
PERNI ROBERT B. ET AL.: "Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 23, 2000, pages 2687 - 2690, XP004219790, DOI: doi:10.1016/S0960-894X(00)00544-8 * |
ZEMBOWER DAVID E. ET AL.: "Robustaflavone, a potential non-nucleoside anti-hepatitis B agent", ANTIVIRAL RESEARCH, vol. 39, no. 2, 1998, pages 81 - 88 * |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4909068B2 (ja) * | 2003-02-14 | 2012-04-04 | グラクソ グループ リミテッド | カルボキサミド誘導体 |
JP2006517574A (ja) * | 2003-02-14 | 2006-07-27 | グラクソ グループ リミテッド | カルボキサミド誘導体 |
WO2005000308A3 (fr) * | 2003-05-15 | 2005-03-24 | Rigel Pharmaceuticals Inc | Procedes d'identification des inhibiteurs de la polymerase vhc-ns5b et utilisations associees |
WO2005000308A2 (fr) * | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Procedes d'identification des inhibiteurs de la polymerase vhc-ns5b et utilisations associees |
WO2005080388A1 (fr) | 2004-02-20 | 2005-09-01 | Boehringer Ingelheim International Gmbh | Inhibiteurs de la polymerase virale |
EP2626354A1 (fr) | 2004-02-20 | 2013-08-14 | Boehringer Ingelheim International GmbH | Inhibiteurs de la polymérase virale |
US8163766B2 (en) | 2005-11-21 | 2012-04-24 | Amgen Inc. | Beta-secretase modulators and methods of use |
WO2007061670A1 (fr) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Modulateurs de beta-secretase et procedes d'utilisation associes |
WO2007062007A1 (fr) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Modulateurs de la bêta-secrétase et procédés d'utilisation de ceux-ci |
WO2007061930A1 (fr) | 2005-11-21 | 2007-05-31 | Amgen Inc. | Modulateurs de beta-secretase et procedes d'utilisation |
US7973047B2 (en) | 2005-11-21 | 2011-07-05 | Amgen Inc. | Beta-Secretase modulators and methods of use |
US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
US7838676B2 (en) | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
JP2009542690A (ja) * | 2006-07-05 | 2009-12-03 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規阻害剤 |
WO2008005511A3 (fr) * | 2006-07-05 | 2008-07-31 | Intermune Inc | Nouveaux inhibiteurs de la réplication du virus de l'hépatite c |
WO2008005511A2 (fr) * | 2006-07-05 | 2008-01-10 | Intermune, Inc. | Nouveaux inhibiteurs de la réplication du virus de l'hépatite c |
EP2494991A1 (fr) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Polythérapie pour le traitement de l'infection par VHC |
US8633315B2 (en) | 2007-05-25 | 2014-01-21 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US8552181B2 (en) | 2007-05-25 | 2013-10-08 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
WO2008147544A1 (fr) | 2007-05-25 | 2008-12-04 | Amgen Inc. | Composés d'hydroxyéthylamine substitués en tant que modulateurs de la bêta-sécrétase et méthodes d'utilisation |
US8163909B2 (en) | 2007-05-25 | 2012-04-24 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US8173810B2 (en) | 2007-05-25 | 2012-05-08 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US7951838B2 (en) | 2007-11-14 | 2011-05-31 | Amgen Inc. | Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use |
US8633228B2 (en) | 2008-08-01 | 2014-01-21 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and pest controlling method |
US9084420B2 (en) | 2008-08-01 | 2015-07-21 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and pest controlling method |
US8426447B2 (en) | 2008-09-11 | 2013-04-23 | Amgen Inc. | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use |
US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
WO2011063272A1 (fr) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Composés amino hétéroaryliques comme modulateurs de bêta-sécrétase et procédés d'utilisation |
WO2011063233A1 (fr) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Composés amino hétéroaryles comme modulateurs de la bêta-secrétase et procédés d'utilisation |
WO2011090911A1 (fr) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Composés d'aminohétéroaryle en tant que modulateurs de bêta-sécrétase et procédés d'utilisation |
US9012446B2 (en) | 2010-03-15 | 2015-04-21 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US8883782B2 (en) | 2010-03-15 | 2014-11-11 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
US8497264B2 (en) | 2010-03-15 | 2013-07-30 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
US9296759B2 (en) | 2011-09-21 | 2016-03-29 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9777019B2 (en) | 2011-09-21 | 2017-10-03 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US10196376B2 (en) | 2011-12-21 | 2019-02-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10676429B2 (en) | 2012-08-28 | 2020-06-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
JP2015531772A (ja) * | 2012-08-28 | 2015-11-05 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 融合二環式スルファモイル誘導体並びにb型肝炎の治療のための薬剤としてのその使用 |
US9156839B2 (en) | 2012-08-28 | 2015-10-13 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EA026957B1 (ru) * | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
WO2014033167A1 (fr) * | 2012-08-28 | 2014-03-06 | Janssen R&D Ireland | Dérivés de sulfamoyle bicycliques fusionnés et leur utilisation en tant que médicaments pour le traitement de l'hépatite b |
CN104797561A (zh) * | 2012-08-28 | 2015-07-22 | 爱尔兰詹森科学公司 | 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途 |
AU2013307328B2 (en) * | 2012-08-28 | 2017-10-19 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10995064B2 (en) | 2012-08-28 | 2021-05-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
KR102148237B1 (ko) | 2012-08-28 | 2020-08-27 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 융합 바이사이클릭 설파모일 유도체 및 b형 간염 치료제로서의 그 용도 |
KR20150047136A (ko) * | 2012-08-28 | 2015-05-04 | 얀센 사이언시즈 아일랜드 유씨 | 융합 바이사이클릭 설파모일 유도체 및 b형 간염 치료제로서의 그 용도 |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10941113B2 (en) | 2013-02-28 | 2021-03-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10398677B2 (en) | 2013-04-03 | 2019-09-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10457638B2 (en) | 2013-05-17 | 2019-10-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10377709B2 (en) | 2013-10-23 | 2019-08-13 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10632112B2 (en) | 2014-02-05 | 2020-04-28 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9862707B2 (en) * | 2014-03-26 | 2018-01-09 | Merck Sharp & Dohme Corp. | TrkA kinase inhibitors, compositions and methods thereof |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US11129834B2 (en) | 2016-04-15 | 2021-09-28 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
Also Published As
Publication number | Publication date |
---|---|
KR20030001167A (ko) | 2003-01-06 |
KR100713137B1 (ko) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003002518A1 (fr) | Nouveaux derives de 2,4-difluorobenzamide utilises comme agents antiviraux | |
KR100798579B1 (ko) | 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물 | |
WO2018043747A1 (fr) | Agent contre le virus de l'hépatite b | |
JP2020526569A (ja) | 環内チアミジノアミド−アリールアミド系化合物及びb型肝炎を治療するためのその用途 | |
US20150218159A1 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
US6608058B2 (en) | 6-methylnicotinamide derivatives as antiviral agents | |
US7276501B2 (en) | 6-(4-substituted-anilino)pyrimidine derivatives, method for preparation thereof and antiviral pharmaceutical composition comprising the same | |
WO1998054140A1 (fr) | Nouveaux derives de terephthalamide | |
KR100566194B1 (ko) | 신규의 3-니트로피리딘 유도체 및 그를 포함하는 약학적조성물 | |
WO2001038306A9 (fr) | Nouveaux derives de la 3-nitropyridine et preparations pharmaceutiques les contenant | |
US6743795B1 (en) | 3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives | |
KR100566193B1 (ko) | 신규의 3-니트로피리딘 유도체 및 그를 포함하는 약학적조성물 | |
KR100661081B1 (ko) | 항바이러스제로 유용한 6-메틸니코틴아미드 유도체 | |
JP2005530802A (ja) | ピロールのアシル二環式誘導体 | |
KR100566188B1 (ko) | 신규의 5-피리미딘카르복스아미드 유도체 및 그를포함하는 약학적 조성물 | |
KR100609490B1 (ko) | 항바이러스제로 유용한 6-메틸니코틴아미드 유도체 | |
US6762189B1 (en) | 5-pyrimidinecarboxamide derivatives and the pharmaceutical compositions containing said derivatives | |
KR100566189B1 (ko) | 신규의 5-피리미딘카르복스아미드 유도체 및 그를포함하는 약학적 조성물 | |
WO2004108719A1 (fr) | Derives de 2-[2-(4-morpholino)ethylamino]pyridine, leur procede de preparation et composition pharmaceutique antivirale les comprenant | |
WO2001038308A1 (fr) | Nouveaux derives de 5-pyrimidinecarboxamide et compositions pharmaceutiques renfermant ces derives | |
MXPA05003159A (es) | Derivados de 6-metilpiridina, metodo para su preparacion y composicion farmaceutica antiviral que lo contiene. | |
CN101146797A (zh) | 用于治疗炎性疾病的作为p38map-激酶抑制剂的4-′2-(环烷基氨基)嘧啶-4-yl!-3-(苯基)-咪唑啉-2-酮衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |